I am not a professional advisor. Seek professional advice before investing or trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I didn't take it as a prediction, but rather some good technical analysis.
Oh... there you are! lol just mentioned you in my last post. Thanks DAVE!!!!
Well... that would be nice, but it's not necessary. He could be quite impactful without a reveal. Also hoping @djhfsu (Dave) can give us any important updates realtime.
Agreed. I couldn't have said it any better.
Hahaha for sure :)
And remember... 16:00 CET (Central European Time) is 11am EST for us.
Top secret ;) Just kidding. Notice on those two days and throughout the other days there are many "panel" discussions. I don't know who's on all those panels, but I would imagine he will be in all the right places. Remember... he's successfully guided 7 other companies through the FDA process. This isn't his first rodeo.
And as someone else has pointed out, here's a list of investors attending. Now I understand why so many investors.
https://www.sachsforum.com/20bef-investors.html
Hey gang... I was just combing through the topics to be covered on Monday's Biotech Conference... I thought this was going to be a medical conference, but it looks a whole lot more like an "Investors Conference for investing in Biotech Companies"... beautiful!
Have a look at the topics on days 2 & 4...
Day 2: BioTech & HealthTech Capital Investment Day
Bio-Pharma in a New Era Panel
Accessing US Capital Markets from Europe Panel
IPO Bootcamp: “The IPO Process & the Secrets to Successful Execution”
Revolution in Cell Based Therapies Across Therapeutics Panel & Showcase
VC & Private Equity: Addressing All Opportunities, Including Crossover Transactions Panel & Showcase
Early Stage Investment Panel
Day 4: Neuroscience Investor Day
CNS Partnering & DealMaking Panel & Showcase
Progress in AD & PD Panel & Showcase
Advanced Therapeutics Panel & Showcase
Advances in NeuroTech, Software & Diagnostics Panel
Medical Cannabis in Europe Panel
Industry & Investor Roundtable
https://www.sachsforum.com/20bef-about.html
and now a 1.3M share purchase
23 blocks of 10,000 shares each???
More like short squeeze... hope u weren't short.
In our study, we've found that 19 out of 21 chickens we've tested do indeed demonstrate chickens are good source of protein, and we are about to announce soon a side-dish that will be served with the chicken, once the first chickens cross the road double-blindfolded.
The pool is proof!
Cheeto lol
Dude isill...
By "our team", I wasn't referring to the investors here... I was referring to the professional leadership team working through the fda process. So I agree with what you said... I just think you misunderstood me.
That's an awesome flip. Nice job. I wasn't here at .04c... wish I were, but I wasn't. I would love to have a 191k win... noth'n wrong with that.
If you've been burned over the past 35 years, I can understand your distaste. I myself would also not hold an otc penny under any other circumstance, so I understand you wanting to warn/educate others... but if you're attempting to manipulate price with fear, that's not cool.
Oh... and maybe also your statement that Covid should kill off all the weak people in our society as a population control mechanism. I thought that was a horrific statement.
I thought you were leaving us??? I was looking forward to it. I had a feeling your were full of crap.
Same here. I'm moving some money around, and hoping it clears soon enough.
For anyone wanting to watch the live broadcast of "The U.S. CDC Director testifies to Senate on coronavirus response".
Expected to talk about treatments...
Hey Pnnymn...
I think investors are becoming impatient or nervous and taking their money to other opportunities in the meantime to make a few bucks while waiting for "October" to swing around. Also, the charts are pointing to a dip towards support, so traders are playing that game as well.
I see that as a short-sighted. I'm long. I'll wait it out. Here's why...
How often do you get a company with a breakthrough solution to a worldwide problem, who has the right connections and experience to deliver that solution, and you are able to get in at a $1B market cap?
If an FDA announcement comes, it is likely to come outside market hours, or they will halt trading to make the announcement. Either way, I'm pretty sure the stock will be long-gone from these levels before the typical retail investor is able to get in.
I'm not willing to risk missing the FDA announcement or any other significant news, as it could come at any moment between now and the next 45 days.
If I KNEW FOR CERTAIN the stock was going to be in the dollars-range within the next 45 days, I wouldn't be concerned at all about interim price swings. Now... I'm not certain, but I do have confidence in the leadership team's experience and connections, what we know about the drug's prior performance (and future potential), and the FDA progress so far.
(This is all my opinion only and NOT trading or investing advice. I could be dead wrong.)
Mike Irwin on Twitter is suggesting...” Rlf-100 is the go to therapeutic..next is Brilacidin( late to trials). Love Humanigen.. but Brilacidin complements Rlf 100 in the immune response realm, and adds additional antiviral PLUS antibacterial component! Think Searcy!”
The whole therapeutics sector will get lift once all this data starts hitting... it will grab attention.
Ok good... so we will see you then. Take care kmack... and good luck bud.
Bachem posted some new jobs for California again yesterday and today. Do these jobs look potentially related to Relief?
https://careers.bachem.com/job/Torrance-Production-Chemist-II-CA-90501/586637401/
https://careers.bachem.com/job/Torrance-Data-Specialist-CA-90501/615302301/
https://careers.bachem.com/job/Torrance-Senior-Scientist%2C-Production-CA-90501/615299601/
https://careers.bachem.com/job/Torrance-Production-Document-SupportQuality-Specialist-CA-90501/615308801/
You're welcome. You're not alone. We are all on the edge of our seats waiting for PR, but really FDA is all that matters... until then, its excruciating lol.
My thoughts...
I can understand the poster's frustration with lack of PR. People only feel confident when certainty is at hand. Everyone wants to make huge profits quick, easy and without risk. But that's not what we have here.
We are not big pharma with all eyes on us. What we have is an OTC penny stock that most investors will not (or cannot) touch. Heck... most people don't even know we exist! That means there is a small group of investors (us) and the occasional batch of traders/flippers that pop in & out from time to time, and we've been moving the price around a few pennies here and there. That means this company (and perhaps a couple others in the therapeutics category) has so far been the best kept secret. Assuming we are all correct and our DD has not lead us down the wrong path, we (the initial investors) have first-mover advantage.
The interim period before official PR hits will be scary and painful. Heck... I was also hoping to see some stronger PR by now, but I understand the magnitude of what we could be releasing to the world, the enormous task at hand to make that happen, the political and big pharma pressures, etc. If we need to sit in silence and darkness for a while in order for our team to get this through FDA, then I'm ok with that. Yes... I would prefer to see the stock drift up each day so that I have zero losses on my holdings, but if we get positive FDA news, these pennies will be meaningless.
I don't know why I feel compelled to speak my thoughts and position. If I'm wrong, I certainly wouldn't want to be the one to lead anyone down the wrong path. Everyone has to make their own decision, just like I do. Its not easy. I have my own doubts, but I think them through, form an assessment, and remain open to reassessing as new information comes in.
Yes... we could lose nearly everything if the FDA denies us... I understand that risk. But if my DD and gut instincts are correct, I think what we have here is a rare opportunity to be invested very early in a company that is on the brink of a significant discovery. I'm waiting patiently through the uncertain times, because I believe we're on to something big.
Hey Penny... the conference isn't this week... you might be confused with the mid-year financial report being released today. Here's a quick assessment...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158291569
Its because you are trying to search for the trail number with the word "NOTE" on the end. An irresponsible post can cause panic in the rush to evaluate the financial report before the opening bell. Please be careful.
https://www.clinicaltrials.gov/ct2/show/NCT04311697
I've scanned the report. I plan to go through it in detail and provide further analysis, but here are my initial thoughts:
Overall, the report looks great to me. It doesn't throw out any shocking negative surprises that I can see, it confirms much of what we already suspected, and it provides some new insights... all of which I was hoping to see... I'm pleased.
As for the Swiss sell off, I've scanned their message boards. Now, I'm no accountant or financial expert, but it looks like some of the Swiss may have seen the Aviptadil valuation as an indicator of Relief's forecast of total expected future revenues from Aviptadil. This would be incorrect, as the value assigned to Aviptadil is an "accounting" value used for depreciation and taxation purposes, and does not necessarily represent the true worth of the asset and all its forecasted revenues (especially since they cannot account for FDA approval yet)... someone please correct me if I'm wrong. It looks like some of the Swiss are starting to catch on to their incorrect assessment, and thus the stock price is drifting back up. I'll take a closer look at this, but wanted to give everyone some direction for their own investigation.
(The above comments are my opinion. I am not an expert and these are my layman assessments. As usual, my comments are not to be considered investment advice.)
Well... as Belfort had pointed out to me, the report may be light on answers, since many of my questions may fall past the reporting period, but we may get some clues.
The corporate calendar shows they will publish a half-year report...
https://relieftherapeutics.com/corporate-calendar/
I assume that's going to be an interim financial report like they did last year...
https://relieftherapeutics.com/wp-content/uploads/2019/09/2019-RTH-Financial-Statements-Interim-final.pdf
Assuming we get the Half-Year Report tomorrow, here are some of the things I’m looking for. Did I miss anything?
1) What does the Share Capital section of the report show? What are the current total and outstanding shares?
2) Is Dr. Ram, Peter, Javitt, Neuro or anyone else now considered a major shareholder or received any shares or compensation?
3) If they generated any revenue, what was it from? Not expecting any/much, but it would be interesting to see if they charged for the trial drugs, and if so, how much?
4) How much of the remaining GEM Share Subscription Facility (CHF $43.8 million) did they use and how much (if any) remains available for drawdown?
5) What other sources of cash did they get and how much? Princeton Angels?
6) How much money did they actually burn through for trials and other business activities?
7) How much cash do they have remaining on hand?
8) Are there any updated comments about how much money they need to finalize trials, infrastructure, ramp up, compensation, etc?
9) Did they redo the Aviptadil impairment test in light of the new Covid-19 application? If so, what is the new valuation, and what details do they provide in the accompanying Sensitivity Analysis?
10) Are there any partnership comments regarding NeuroRX, manufacturers, or distributors?
11) Where there any other staffing changes other than hiring the Chief Medical Officer for European expansion?
12) Do they make any comments about hiring a CEO or other key positions?
13) Which Execs and Board members received compensation (who’s the core group remaining)?
14) And of course… any updates on trial results, DMC, etc?
Anything else you guys are looking for?
I don't think they would do it until at least the first IV study comes back from the FDA... then they have serious leverage to negotiate and do valuations. But even then, they might hold out for the inhaler too.
Also, keep in mind that they've started a separate effort for the European market with a separate CMO and trials, so maybe they end up going a licensing route, rather than a total sale, where they license the rights out to 1 or several companies in each country.
But honestly, I'm no expert on mergers & acquisitions.
Thanks Dave! That's awesome! If you find a way to record it (even with your cell phone pointed at your computer), I know at least 1 person who would love to see it :) Looking forward to your observations and comments as well!
Squeeze it up baby!
Not having private messages is no big deal, but if you run out of public messages, that would be unfortunate, because your contribution is much appreciated. I'm cheap too and did free for a while before biting the bullet. The value of communicating with this group eventually outweighed the $13.
My bet is its a lot less now
Just fyi... "Mr. Dreano resigned from his position of Group CFO and other roles and functions with effective date 30 June 2019."
And... "Dr. Hédou assumesthe role of CEO since 17 February 2017 after the resignation of Mr. Petrone. Dr. Hédou resigned from his position of Group CEO with effective date 30 June 2019."
And... we might see an update tomorrow when the Half-Year report is released, because the company does have some...
12.3 Conditional Share Capital
The conditional share capital of the Company as at 31 December 2019 was TCHF 10’569 (2018: TCHF 7’628), consisting of 1’056’959’622 (2018: 762’800’430) registered shares with a par value of CHF 0.01 each, of which 190’000’000 (2018: 190’000’000) to be used for share options for members of the Board of Directors, Executive Management, employees and consultants as well as 866’959’622 (2018: 572’800’430) to be used for the exercise of conversion option rights granted in connection with bonds, notes or similar debt instruments issued by the Company.